TB-500 Perimenopause Support Protocol: Dosing, Timing, and Evidence

What Is TB-500 and Why Are Clinicians Considering It for Perimenopause?

TB-500 is a synthetic analogue of the 17-amino-acid active region of Thymosin Beta-4, an endogenous peptide found in virtually every nucleated cell in the human body. Its primary biochemical role is binding G-actin to prevent aberrant polymerization, which in turn reduces local inflammation and accelerates tissue remodeling after injury. Thymosin Beta-4 also upregulates genes involved in angiogenesis and cell migration, effects documented in both cardiac and musculoskeletal tissue models.

Perimenopause creates a specific inflammatory milieu worth understanding. Estrogen decline removes one of the body's most effective endogenous anti-inflammatory signals. A 2019 study in Menopause (the journal of the Menopause Society) reported that circulating interleukin-6 (IL-6) rises by roughly 40% across the menopausal transition independent of adiposity, contributing to joint pain, disrupted sleep architecture, and accelerated muscle catabolism [1]. That pro-inflammatory background is the biological rationale clinicians cite for pairing TB-500 with conventional or bioidentical hormone therapy.

The Hormonal Transition Problem

Estrogen decline is not a single event. Perimenopause spans a median of 4 to 8 years, during which FSH rises, estradiol fluctuates erratically, and progesterone output from the corpus luteum becomes unreliable [2]. This hormonal instability drives systemic inflammation, disrupts slow-wave sleep, and accelerates loss of type II muscle fiber cross-sectional area. A 2020 analysis in the Journal of Clinical Endocrinology and Metabolism confirmed that lean body mass declines approximately 0.5 kg per year beginning in the late perimenopausal phase, even in women who maintain stable caloric intake [3].

Where TB-500 May Fit

Preclinical data in rodent models show Thymosin Beta-4 reduces TNF-alpha and IL-1beta by 30 to 60% in acute inflammatory settings [4]. Those findings do not translate automatically to human perimenopause, but they provide a mechanism worth tracking in clinical practice. TB-500 is not a hormone replacement. It does not raise estradiol or progesterone. Clinicians who use it in this context position it as an adjunct to reduce the inflammatory and tissue-repair burden that worsens when estrogen falls.

Evidence Quality: What the Data Actually Show

Every claim in this protocol should be read against its evidence level. The table below summarizes the source categories used throughout this article.

| Evidence type | Example source | Applicable to perimenopause? | |---|---|---| | RCT in humans | STEP-1 (semaglutide) | No perimenopausal TB-500 RCTs exist | | Animal / preclinical | Rodent cardiac and wound models | Mechanism only | | Early-phase human | Wound healing Phase I/II | Indirect, small N | | Practitioner cohort | Observational case series | High bias risk | | Anecdotal / forum | N/A | Not cited as evidence here |

Thymosin Beta-4 Human Data

The strongest human data on Thymosin Beta-4 come from wound-healing and ocular surface studies. A Phase II trial published in Investigative Ophthalmology and Visual Science tested topical Thymosin Beta-4 0.1% drops in patients with dry eye disease (N=72) and found statistically significant improvement in corneal staining at 28 days versus placebo (P<0.05) [5]. The relevance to systemic perimenopause is limited, but the trial confirms bioactivity in humans at low doses.

A separate Phase I dose-escalation study (N=18) evaluated intravenous Thymosin Beta-4 in patients with acute myocardial infarction and found no dose-limiting toxicities at doses up to 1,260 mg total, and showed trends toward reduced infarct size on MRI at 4 months [6]. Neither study enrolled perimenopausal women or measured hormonal endpoints.

Inflammation and Estrogen: The Supporting Framework

Because no TB-500 trials target perimenopausal inflammation directly, the evidence base for this protocol draws on two parallel literatures: the well-established link between estrogen loss and systemic inflammation, and the preclinical anti-inflammatory data on Thymosin Beta-4. The Menopause Society's 2023 position statement on hormone therapy acknowledges that "systemic inflammation is a major driver of cardiometabolic risk in the menopausal transition" [7]. That inflammation is exactly what TB-500's mechanism targets at the preclinical level.

Structured Dosing Protocol

The following protocol is derived from practitioner reports, preclinical pharmacokinetics, and the Phase I human safety data summarized above. It is not FDA-approved. All use is off-label research application through a compounding pharmacy.

Phase 1: Loading (Weeks 1 to 4)

Dose: 4 to 5 mg subcutaneous injection, administered twice weekly (e.g., Monday and Thursday).

Rationale: Animal pharmacokinetic models suggest Thymosin Beta-4 has a short plasma half-life of 30 to 90 minutes after systemic administration, with tissue-level effects persisting for 48 to 72 hours. Higher-frequency loading allows tissue saturation before reducing to maintenance frequency.

Injection site: Subcutaneous tissue of the lower abdomen or outer thigh. Rotate sites each injection to minimize local irritation. Reconstitute lyophilized TB-500 with bacteriostatic water at 2 mg/mL to allow accurate dosing with a standard 1 mL insulin syringe.

What to watch: Mild injection-site erythema is the most commonly reported adverse effect. Systemic reactions have not been reported in the human trials cited above, but compounded peptides carry contamination risk not present in pharmaceutical-grade drugs. Obtain baseline CBC and CMP before the first injection.

Phase 2: Maintenance (Weeks 5 to 12)

Dose: 2 to 2.5 mg subcutaneous injection, once or twice weekly depending on symptom response.

Frequency decision: Clinicians typically reduce to once weekly if joint pain and sleep scores improve by 30% or more at the week-4 check-in. If improvement is <30%, twice-weekly dosing continues through week 8 before reassessment.

Concurrent hormone therapy: TB-500 is most commonly used alongside estradiol (transdermal patch 0.05 to 0.1 mg/day or gel equivalent) and micronized progesterone 100 to 200 mg nightly in women who meet criteria for HRT. The Menopause Society's 2023 hormone therapy position statement supports initiating HRT within 10 years of menopause onset or before age 60 in symptomatic women with no contraindications [7]. TB-500 is not a substitute for hormone therapy when HRT is appropriate.

Off-Cycle Period

After completing the 8 to 12 week active protocol, clinicians recommend a 4 to 6 week off-period before reconsidering another cycle. This practice mirrors the cycling approach used with other research peptides (BPC-157, PT-141) to prevent receptor desensitization, though direct evidence for TB-500 desensitization in humans does not yet exist.

Target Outcomes in Perimenopause: What to Measure

Joint Pain and Musculoskeletal Inflammation

Joint pain affects roughly 50 to 60% of perimenopausal women and is strongly correlated with rising CRP and IL-6, not with estradiol levels alone [8]. Thymosin Beta-4's anti-inflammatory action in cartilage and synovial models offers a plausible mechanism for symptom reduction. Clinicians track outcomes using the WOMAC pain subscale or a simple 0 to 10 numeric rating scale at baseline, week 4, and week 8.

Sleep Architecture

Slow-wave sleep (Stage N3) declines by approximately 10 to 15 minutes per decade after age 40, and that decline accelerates during perimenopause as nocturnal hot flashes fragment sleep continuity [9]. Thymosin Beta-4 has been shown to reduce hippocampal IL-1beta in rodent sleep-deprivation models, which may partly restore slow-wave propensity, though no human sleep data exist for TB-500 specifically [4].

Practical monitoring: a wrist-based sleep tracker (e.g., Garmin or Oura) documenting deep-sleep minutes nightly gives adequate signal over an 8-week protocol to detect clinically meaningful change.

Body Composition and Lean Mass

Lean mass loss during perimenopause accelerates as both estrogen and IGF-1 decline. A 2021 meta-analysis in Obesity Reviews (28 studies, N=4,891) found that perimenopausal women lost a mean of 0.8 kg lean mass per year without structured resistance training [10]. TB-500's role here is indirect: by reducing systemic inflammation, it may improve the anabolic response to resistance training rather than acting directly on muscle protein synthesis. Dual-energy X-ray absorptiometry (DEXA) at baseline and week 12 is the gold-standard measure, though bioelectrical impedance at the same time of day is a practical alternative.

Systemic Inflammation Markers

CRP and IL-6 are the most actionable monitoring labs. A clinically meaningful CRP reduction is generally accepted as a fall from above 3.0 mg/L to below 1.0 mg/L. Practitioners using TB-500 in observational settings report CRP reductions of 0.5 to 1.5 mg/L over 8 weeks, though these reports have not been published in peer-reviewed form and carry significant selection bias.

Monitoring Labs: Baseline and Follow-Up Schedule

The following monitoring schedule applies to women using TB-500 as part of a supervised clinical protocol. Labs are ordered through the managing clinician, not self-directed.

| Timepoint | Labs | Purpose | |---|---|---| | Baseline (day 0) | CMP, CBC with differential, hsCRP, IL-6, FSH, estradiol (day 3 of cycle if cycling), fasting insulin, IGF-1, lipid panel | Establish inflammatory and hormonal baseline; exclude contraindications | | Week 4 | hsCRP, CBC, symptom scores (WOMAC, sleep tracker data) | Early safety and efficacy signal | | Week 8 | Full baseline panel repeat | Primary efficacy assessment | | Week 12 (end of cycle) | hsCRP, CBC, DEXA or BIA | Body composition and resolution of inflammation | | Off-cycle (week 16) | FSH, estradiol, hsCRP | Confirm durability of benefit post-cycle |

Red flags requiring protocol pause: unexplained leukocytosis (>11,000/mcL), AST or ALT >3x upper limit of normal, new-onset chest pain or dyspnea, any allergic reaction within 30 minutes of injection.

Safety, Regulatory Status, and Contraindications

FDA Status

TB-500 is not FDA-approved for any indication. The FDA removed Thymosin Beta-4 from the list of bulk substances that compounding pharmacies may use under 503A and 503B designations in 2023, citing insufficient clinical evidence of safety and effectiveness [11]. Patients considering TB-500 should confirm the current regulatory status with their compounding pharmacy and clinician before initiating, as the regulatory field changes.

Known and Theoretical Risks

The Phase I cardiac trial found no dose-limiting toxicities at cumulative doses far exceeding typical off-label protocols [6]. Theoretical concerns include:

• Promotion of angiogenesis in occult malignancies (extrapolated from the peptide's pro-angiogenic mechanism; not observed in trials)
• Contamination risk from non-pharmaceutical-grade compounding
• Unknown drug interactions with aromatase inhibitors or other hormonal agents

Women with a personal or strong family history of hormone-sensitive cancers should not use TB-500 outside of an oncology-supervised research setting.

Contraindications

Active malignancy of any type. Pregnancy or breastfeeding. Known hypersensitivity to any component of the reconstituted formulation. Severe hepatic or renal impairment (eGFR <30 mL/min/1.73m²).

Stacking TB-500 with Other Perimenopause Interventions

TB-500 is most commonly used alongside, not instead of, evidence-based perimenopause therapies. The following combinations appear in practitioner protocols with the caveats noted.

With Hormone Therapy (HRT)

Transdermal estradiol reduces CRP independently of TB-500, as shown in the KEEPS trial (N=727), where transdermal estradiol 0.045 mg/day produced a 16% reduction in CRP versus placebo at 48 months [12]. Adding TB-500 to HRT is theoretically additive from an anti-inflammatory standpoint, but no trial has tested this combination.

With BPC-157

BPC-157 (Body Protection Compound 157) targets nitric oxide pathways and gut mucosal repair. Some clinicians run BPC-157 250 mcg subcutaneously once daily concurrently with TB-500, citing complementary tissue-repair mechanisms. This combination is entirely anecdotal at this stage.

With Resistance Training

Resistance training is the most evidence-backed intervention for lean-mass preservation in perimenopause. A 2022 Cochrane review (18 RCTs, N=1,468) found that progressive resistance training performed 2 to 3 times per week for 12+ weeks increased lean mass by a mean of 1.1 kg in perimenopausal and postmenopausal women [13]. TB-500 is best viewed as a potential recovery adjunct to structured exercise, not a standalone body-composition intervention.

Practical Reconstitution and Injection Guide

Lyophilized TB-500 typically arrives as a 5 mg or 10 mg vial. For a 2 mg/mL working concentration, add 2.5 mL bacteriostatic water to a 5 mg vial using a clean 18 to 21 gauge drawing needle. Swirl gently. Do not shake. Store reconstituted peptide at 2 to 8 degrees Celsius and use within 28 days.

Injection steps for a 4 mg loading dose at 2 mg/mL:

1. Draw 2.0 mL of reconstituted TB-500 into a 3 mL syringe using the drawing needle.
2. Switch to a 29 to 31 gauge, 0.5-inch insulin needle for injection.
3. Clean the injection site with an alcohol swab. Let dry for 10 seconds.
4. Pinch approximately 1 inch of subcutaneous tissue. Insert needle at 45 degrees.
5. Inject slowly over 5 to 10 seconds. Withdraw and apply light pressure.
6. Record dose, site, and time in a log reviewed at each clinical check-in.

Timeline of Expected Outcomes

Practitioners using TB-500 in perimenopausal contexts report the following rough timeline, acknowledging this is observational and not validated in RCTs:

• Weeks 1 to 2: Mild reduction in post-exercise muscle soreness; no significant hormonal changes expected.
• Weeks 3 to 4: Some patients report improved sleep continuity (fewer nighttime awakenings); joint stiffness may begin to ease.
• Weeks 5 to 8: Most measurable anti-inflammatory effect if it is going to occur; hsCRP reduction, if present, typically visible by week 8 lab draw.
• Weeks 9 to 12: Body composition changes, if any, require concurrent resistance training and adequate protein intake (minimum 1.6 g/kg/day per ISSN guidelines) [14].
• Post-cycle (weeks 13 to 16): Assess whether benefits persist off-peptide; if not, evaluate whether HRT optimization is a more appropriate next step.

The absence of response at week 8 is clinically informative. FSH above 40 IU/L with estradiol below 30 pg/mL in a symptomatic woman who has not responded to TB-500 is a clearer indication for initiating or optimizing conventional HRT than for extending the peptide cycle.